| Literature DB >> 33804977 |
Miguel Ángel Sánchez-Tena1, Clara Martinez-Perez1, Cesar Villa-Collar1, Cristina Alvarez-Peregrina1.
Abstract
BACKGROUND: The main objective of this study was to use citation networks to analyze the relationship between different publications on the impact of COVID-19 at an ocular level and their authors. Furthermore, the different research areas will be identified, and the most cited publication will be determined.Entities:
Keywords: COVID-19; COVID-19 conjunctivitis; SARS-CoV-2; ocular disease
Year: 2021 PMID: 33804977 PMCID: PMC8036864 DOI: 10.3390/jcm10071340
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Number of publications per year.
Characteristics of the main countries.
| Group | Color | Main Countries | Publications | Centrality | Degree | Half-Life | Connections |
|---|---|---|---|---|---|---|---|
| 1 | Red | EE. UU | 105 | 0.01 | 5 | −0.5 | 60 |
| 2 | Green | Germany | 22 | 0.04 | 16 | −0.5 | 43 |
| 3 | Blue | Switzerland | 6 | 0.12 | 17 | −0.5 | 14 |
| 4 | Yellow | The Netherlands | 7 | 0.15 | 13 | −0.5 | 12 |
Figure 2Collaboration between countries.
The 10 research areas with the highest number of publications.
| Category | Frequency | Centrality | Degree | HalfLife |
|---|---|---|---|---|
| Ophthalmology | 263 | 0.18 | 11 | −0.5 |
| General & Internal Medicine | 138 | 0.00 | 11 | −0.5 |
| Research & Experimental Medicine | 78 | 0.25 | 17 | −0.5 |
| Infectious Diseases | 53 | 0.06 | 10 | −0.5 |
| Neurosciences & Neurology | 31 | 0.10 | 8 | −0.5 |
| Public, Environmental & Occupational Health | 25 | 0.03 | 5 | −0.5 |
| Surgery | 18 | 0.03 | 5 | −0.5 |
| Clinical Neurology | 8 | 0.04 | 6 | −0.5 |
| Pediatrics | 7 | 0.00 | 3 | –0.5 |
| Pharmacology & Pharmacy | 7 | 0.07 | 10 | –0.5 |
The 10 authors with the highest number of publications.
| Author | Number of Publications | Total Citations | Citation Average | Centrality | Degree | Connections | |
|---|---|---|---|---|---|---|---|
| Sharma N | 9 | 2 | 12 | 1.56 | 0.00 | 9 | 175 |
| Bandello F | 8 | 4 | 29 | 5.17 | 0.00 | 8 | 151 |
| Agrawal R | 7 | 3 | 167 | 30.00 | 0.08 | 5 | 428 |
| Shetty R | 7 | 2 | 12 | 2.67 | 0.01 | 11 | 74 |
| Sachdev MS | 7 | 2 | 12 | 2.00 | 0.00 | 8 | 138 |
| Sinha R | 5 | 2 | 10 | 2.40 | 0.00 | 8 | 125 |
| Arriola-Villalobos P | 4 | 2 | 11 | 3.50 | 0.00 | 1 | 144 |
| Khamar P | 4 | 2 | 8 | 2.67 | 0.00 | 8 | 43 |
| D´souza S | 4 | 1 | 11 | 2.50 | 0.00 | 9 | 50 |
| Levy J | 4 | 1 | 7 | 3.00 | 0.00 | 2 | 53 |
The 10 institutions with the highest number of publications.
| Category | Frequency | Centrality | Degree | Half-Life | Connections |
|---|---|---|---|---|---|
| All India Institute of Medical Sciences | 15 | 0.02 | 15 | −0.5 | 74 |
| LV Prasad Eye Institute | 13 | 0.02 | 13 | −0.5 | 24 |
| Ctr Sight | 12 | 0.04 | 15 | −0.5 | 46 |
| Harvard Medical School | 10 | 0.10 | 8 | −0.5 | 15 |
| Tan Tock Seng Hospital | 9 | 0.11 | 18 | −0.5 | 59 |
| Johns Hopkins University | 8 | 0.03 | 2 | −0.5 | 6 |
| Stanford University | 7 | 0.39 | 11 | −0.5 | 11 |
| National University of Singapore | 7 | 0.10 | 15 | −0.5 | 54 |
| University of Miami | 7 | 0.21 | 6 | −0.5 | 9 |
| Sankara Nethralaya | 6 | 0.03 | 15 | −0.5 | 33 |
The 10 journals with the highest number of publications.
| Journal | Total Publications | Impact Factor | Quartile Score | SJR (2019) | Citations/Docs | Total Citations | Country | |
|---|---|---|---|---|---|---|---|---|
| Indian Journal of Ophthalmology | 53 | 1.25 | Q4 | 0.48 | 1.239 | 1082 | 47 | India |
| Graefe’s Archive for Clinical and Experimental Ophthalmology | 17 | 2.39 | Q2 | 1.26 | 2.811 | 2273 | 96 | Germany |
| Ocular Immunology and Inflammation | 14 | 2.11 | Q2 | 0.78 | 2.331 | 844 | 53 | United Kingdom |
| Ophthalmology | 14 | 8.47 | Q1 | 4.42 | 8.476 | 6778 | 229 | Netherlands |
| Current Opinion in Ophthalmology | 12 | 2.98 | Q1 | 1.23 | 3.288 | 870 | 83 | United States |
| Ophthalmologe | 11 | 0.74 | Q4 | 0.26 | 0.655 | 306 | 38 | Germany |
| Eye | 11 | 2.45 | Q2 | 1.15 | 2.689 | 1930 | 93 | United Kingdom |
| Journal francais d´Ophalmologie | 11 | 0.64 | Q4 | 0.27 | 0.493 | 287 | 29 | France |
| Clinical Ophthalmology | 10 | - | - | 0.96 | 2.077 | 2033 | 50 | New Zeland |
| Acta Ophthalmologica | 8 | 3.36 | Q1 | 1.42 | 3.304 | 2369 | 82 | United States |
The 30 most used keywords.
| Keyword | Frequency | Centrality | Degree | Total Link Strength |
|---|---|---|---|---|
| COVID-19 | 168 | 0.01 | 6 | 485 |
| Coronavirus | 85 | 0.03 | 11 | 352 |
| SARS-COV-2 | 74 | 0.05 | 9 | 309 |
| Ophthalmology | 45 | 0.03 | 6 | 155 |
| Conjunctivitis | 36 | 0.01 | 6 | 154 |
| Telemedicine | 24 | 0.02 | 12 | 77 |
| Infection | 23 | 0.06 | 8 | 96 |
| Transmission | 20 | 0.02 | 9 | 117 |
| SARS | 19 | 0.03 | 7 | 105 |
| Pandemic | 19 | 0.00 | 2 | 52 |
| Coronavirus disease 2019 | 18 | 0.00 | 3 | 71 |
| Outbreak | 15 | 0.01 | 6 | 83 |
| Eye | 15 | 0.00 | 1 | 66 |
| Pneumonia | 14 | 0.03 | 11 | 99 |
| ACE 2 | 14 | 0.08 | 17 | 88 |
| Ocular surface | 14 | 0.05 | 9 | 70 |
| Respiratory syndrome coronavirus | 12 | 0.00 | 4 | 62 |
| Chloroquine | 11 | 0.00 | 9 | 51 |
| Diagnosis | 11 | 0.04 | 11 | 74 |
| Hydroxychloroquine | 10 | 0.02 | 11 | 55 |
| Teleophthalmology | 10 | 0.07 | 11 | 43 |
| Conjunctiva | 9 | 0.01 | 9 | 60 |
| Retinopathy | 9 | 0.02 | 9 | 35 |
| Receptor | 9 | 0.00 | 4 | 56 |
| Lockdown | 9 | 0.00 | 1 | 23 |
| Ocular manifestation | 9 | 0.00 | 3 | 31 |
| Disease | 9 | 0.00 | 3 | 33 |
| Guidelines | 9 | 0.00 | 1 | 26 |
| Inhibition | 8 | 0.06 | 12 | 29 |
| Retina | 8 | 0.03 | 7 | 34 |
Figure 3Link between keywords.
Characteristics of most-used keywords.
| Cluster | Color | Main Keywords | Topic | % |
|---|---|---|---|---|
| 1 | Red | Covid-19, telemedicine, pandemic, teleophthalmology, telehealth | Benefits of teleophthalmology in patients with COVID-19 | 2.39 |
| 2 | Green | SARS-COV-2, respiratory syndrome coronavirus, transmission, infection, pneumonia | Transmission methods | 1.74 |
| 3 | Blue | Ophthalmology, conjunctivitis, sars, outbreak, virus | Ocular manifestations | 1.30 |
| 4 | Yellow | Coronavirus, coronavirus disease 2019, personal protective equipment, children, disease | Personal protective equipment | 0.98 |
| 5 | Violet | Prevention, inhibition, chloroquine, hydroxychloroquine, retinal toxicity | Ocular side effects of treatment in patients with COVID-19 | 0.98 |
Description of the 20 most cited publications on COVID-19 and vision.
| Author | Title | Journal | Year | Citation Index | Links |
|---|---|---|---|---|---|
| Wu et al. [ | Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China | JAMA Ophthalmol. 1 May 2020;138(5):575–578 | 2020 | 229 | 94 |
| Seah et al. [ | Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals | Ocul Immunol Inflamm. 2 April 2020;28(3):391–395 | 2020 | 143 | 66 |
| Lai et al. [ | Stepping up infection control measures in ophthalmology during the novel coronavirus outbreak: an experience from Hong Kong | Graefes Arch Clin Exp Ophthalmol. May 2020;258(5):1049–1055. | 2020 | 111 | 42 |
| Gupta et al. [ | Extrapulmonary manifestations of COVID-19 | Nat Med. July 2020;26(7):1017–1032 | 2020 | 111 | 2 |
| Li et al. [ | Novel Coronavirus disease 2019 (COVID-19): The importance of recognising possible early ocular manifestation and using protective eyewear | Br J Ophthalmol. March 2020;104(3):297–298. | 2020 | 90 | 39 |
| Chen et al. [ | Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease | Br J Ophthalmol. June 2020;104(6):748–751. | 2020 | 79 | 48 |
| Colavita et al. [ | SARS-CoV-2 Isolation From Ocular Secretions of a Patient With COVID-19 in Italy With Prolonged Viral RNA Detection | Ann Intern Med. 4 August 2020;173(3):242–243. | 2020 | 71 | 37 |
| Zhang et al. [ | The evidence of SARS-CoV-2 infection on ocular surface | Ocul Surf. July 2020;18(3):360–362. | 2020 | 51 | 31 |
| Zhou et al. [ | Ocular Findings and Proportion with Conjunctival SARS-COV-2 in COVID-19 Patients | Ophthalmology. July 2020;127(7):982–983. | 2020 | 40 | 26 |
| Romano et al. [ | Facing COVID-19 in Ophthalmology Department | Curr Eye Res. June 2020;45(6):653–658 | 2020 | 39 | 19 |
| Tostmann et al. [ | Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020 | Euro Surveill. April 2020;25(16):2000508 | 2020 | 39 | 4 |
| Olivia Li et al. [ | Preparedness among Ophthalmologists: During and Beyond the COVID-19 Pandemic | Ophthalmology. May 2020;127(5):569–572 | 2020 | 36 | 22 |
| Hong et al. [ | Evaluation of ocular symptoms and tropism of SARS-CoV-2 in patients confirmed with COVID-19 | Acta Ophthalmol. 26 April 2020;10.1111/aos.14445. | 2020 | 34 | 22 |
| Ma et al. [ | Expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in human primary conjunctival and pterygium cell lines and in mouse cornea | Eye (Lond). July 2020;34(7):1212–1219 | 2020 | 31 | 15 |
| Chen et al. [ | Ocular manifestations and clinical characteristics of 535 cases of COVID-19 in Wuhan, China: a cross-sectional study | Acta Ophthalmo. December 2020;98(8):e951–e959. | 2020 | 27 | 18 |
| Scalinci et al. [ | Conjunctivitis can be the only presenting sign and symptom of COVID-19 | DCases. 2020;20:e00774. | 2020 | 26 | 20 |
| Saleem et al. [ | Virtual Ophthalmology: Telemedicine in a COVID-19 Era | Am J Ophthalmol. August 2020;216:237–242 | 2020 | 23 | 7 |
| Korobelnik et al. [ | Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic | Graefes Arch Clin Exp Ophthalmol. June 2020;258(6):1149–1156. | 2020 | 22 | 7 |
| Mishra et al. [ | The impact of COVID-19 related lockdown on ophthalmology training programs in India—Outcomes of a survey | Indian J Ophthalmol. June 2020;68(6):999–1004. | 2020 | 21 | 10 |
| Zhou et al. [ | ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection | Ocul Surf. October 2020;18(4):537–544 | 2020 | 19 | 15 |
Figure 4COVID-19 citation networks and vision.
Information on the citation networks of the 3 main groups.
| Main Cluster | Number of Publications | Number of Citation Links | Number of Citations Median (Range) | Number of Publications with ≥4 Citations | Number of Publications in the 100 Most Cited Publications |
|---|---|---|---|---|---|
| Group 1 | 158 | 604 | 0 (0–94) | 37 | 53 |
| Group 2 | 68 | 84 | 1 (0–7) | 10 | 32 |
| Group 3 | 60 | 87 | 0 (0–40) | 9 | 15 |
Figure 5Citation network in group 1.
Figure 6Citation network in group 2.
Figure 7Citation network in group 3.
Figure 8Citation network of group 1 subclusters.
Main citation network groups from the subcluster in group 1.
| Sub-Cluster | 1 | 2 | 3 |
|---|---|---|---|
| Nº of publications | 103 | 27 | 20 |
| Nº of citation links | 381 | 30 | 17 |
| Most cited publication | Wu et al. [ | Sun et al. [ | Romano et al. [ |
| Main Keywords | Conjunctivitis, retina, glaucoma | Sars-cov-2, Hydroxychloroquine, retinal toxicity | Ocular manifestation, neuro-ophthalmology, optic neuritis |
| Topic of discussion | Ocular characteristics in COVID-19 patients | Ocular risks following the administration of ritonavir, chloroquine and hydroxychloroquine | Neuroophthalmic manifestations in COVID-19 patients |
| Conclusion | A wide spectrum of ocular manifestations might occur, ranging from anterior segment pathologies such as conjunctivitis and anterior uveitis to affectations compromising vision, such as retinitis and optical neuritis. | Evidence to date shows that extreme dosage accelerates retinal toxicity, but within a period of time which is likely to be of many months rather than a few days. | Neuroophthalmological signs and symptoms may appear isolated or associated to neurological disorders. Most common manifestations include headaches, eye pain, vision impairment, diplopia, and secondary cranial pairs palsy associated to Miller Fisher syndrome, Guillain–Barré syndrome or encefalitis and nystagmus. |
Figure 9Core Publications on the COVID-19 and vision citation network.